
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is an innovative biopharmaceutical company utilizing precision medicine to develop anti-cancer therapeutics, with a current focus on their lead program, Stenoparib, for advanced recurrent ovarian cancer. With a strong financial outlook and plans for expansion into both the Danish and US markets, Allarity Therapeutics is poised for success in the rapidly growing precision medicine sector. However, risks to achieving our price target include potential balance sheet and liquidity challenges, uncertainties in clinical trial results and regulatory approvals, and potential competition in the market. Overall, the company offers significant upside potential for investors with its attractive valuation and promising developments in the precision medicine space.
Bears say
Allarity Therapeutics is a clinical-stage biopharmaceutical company focused on developing anti-cancer therapeutics for ovarian and small cell lung cancer. However, based on its recent Q1 results and the lack of guidance or consensus estimates, the company's minimal revenue generation and ongoing net losses are concerning. Additionally, while its DRP platform and lead drug Stenoparib show potential, there are significant risks to attaining regulatory approval and commercial success in a highly competitive PARP inhibitor market. Moreover, the company's low cash and high debt levels are a concern for investors.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares